Gwendolyn Wu
Senior Reporter | LinkedInGwendolyn Wu is a senior reporter at BioPharma Dive covering biotech startups, venture capital, IPOs and the ecosystem that supports them. She was selected as the 2024 McAllister Editorial Fellow by SIIA in recognition for her work on a series of stories examining the world’s first CRISPR medicine. Previously, she authored Bay Briefing, the San Francisco Chronicle’s flagship weekday newsletter, and covered COVID-19 and the business of healthcare for the Houston Chronicle. Outside of the newsroom, Gwendolyn teaches at the California Scholastic Press Association summer workshop for high school journalists, and has led student and early career programs for the Asian American Journalists Association. She has degrees in history and sociology from the University of California at Santa Barbara.
409 articles by Gwendolyn Wu
-
Odyssey, on second try, snags $279M in an IPO
May 7, 2026 -
Angelini to buy Catalyst in $4B play for rare neuro drugs
May 7, 2026 -
CellCentric raises $220M for a ‘transformative’ multiple myeloma medicine
May 6, 2026 -
Cytospire hauls in $83M for a new type of T cell engager
May 5, 2026 -
Arvinas’ ‘Protac’ breast cancer drug cleared by FDA
May 1, 2026 -
Two biotechs raise a combined $556M in latest spurt of IPOs
April 30, 2026 -
Avalyn, in pursuit of better lung drugs, banks $300M in an IPO
April 29, 2026 -
Biotech investors gamble on M&A. Some drugmakers are betting on themselves instead.
April 28, 2026 -
Tortugas debuts with $106M and brain drugs from Hansoh, Eisai
April 21, 2026 -
Serif, Flagship’s latest biotech, aims to make a new kind of genetic medicine
April 21, 2026 -
Kailera nets $625M in one of biotech’s biggest-ever IPOs
April 16, 2026 -
Allogene data suggest ‘off-the-shelf’ CAR-T could delay relapse in lymphoma
April 13, 2026 -
Oricell closes a ‘pre-IPO’ megaround to aim CAR-T at solid tumors
April 10, 2026 -
Chasing a tough-to-treat lung disease, Avalyn plans an IPO
April 9, 2026 -
Jeito Capital, prominent biotech investor, raises $1.2B for next fund
April 8, 2026 -
Gilead continues M&A surge with $3.1B deal for ADC specialist Tubulis
April 7, 2026 -
Ambrosia adds a megaround for obesity drugs
April 1, 2026 -
Merck strikes deal with antibody discovery startup
March 31, 2026 -
Biotech IPOs stayed at slow pace, but grew larger in the first quarter of 2026
March 31, 2026 -
Obesity drugmaker Kailera plans an IPO
March 30, 2026 -
Novartis targets Xolair successor in buyout of startup Excellergy
March 27, 2026 -
Beam posts positive data on base editing treatment for AATD
March 25, 2026 -
RA Capital targets China with latest SPAC deal
March 24, 2026 -
Gilead, with Ouro deal, wagers $1.7B on bispecifics for autoimmune diseases
March 24, 2026 -
Novartis pays $2B to land a startup’s breast cancer drug
March 20, 2026
